Rapinesi C1, Kotzalidis GD, Scatena P, Del Casale A, Janiri D, Callovini G, Piacentino D, Serata D, Raccah RN, Brugnoli R, Digiacomantonio V, Mascioli F,Ferri VR, Ferracuti S, Pompili M, De Pisa E, Di...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. World J Biol Psychiatry. 2014 Aug 20:1-8.
The study compared standard drug treatment (n=10) with drug treatment combined with Brainsway® Deep TMS (Transcranial Magnetic Stimulation ; n=10) for treating mood and substance use disorders through stimulation of the Dorsolateral prefrontal cortex (DLPFC). The study, held over 6 months, included abstinent patients suffering from Alcohol Use Disorder, who also had a previous dysthymic disorder. The study showed that after 20 sessions of Deep TMS, craving and depressive symptoms dropped significantly, suggesting that Brainsway’s Deep TMS is well tolerated and effective as an add-on treatment for alcohol use disorder.